Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Q3 Sales Rise 'Is Milestone', CEO Soriot 'Not Leaving'

Executive Summary

AstraZeneca's third-quarter results show it has emerged from a long decline and returned to growth, fuelled by new products and pipeline, the UK pharma's CEO Pascal Soriot told reporters, adding that he's having too much fun turning the group around to leave any time soon.

Advertisement

Related Content

R&D Heads At GSK & AZ Say Key To Success Lies In Smart Risk Taking
AstraZeneca: DECLARE-TIMI Outcomes May Support Competitive Claim For Farxiga In Heart Failure
AZ's Lynparza PARP Lead Likely To Lengthen With FDA Priority Review
Innate Pharma's Expanded IO AstraZeneca Deal Jump-Starts US Ambitions

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124140

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel